Bluegreen, not about LBP but one of the acquired patents. I would appreciate any post that help make this patent more understandable.
5532216 : Neutralization of non-lipopolysaccharide compounds by
bactericidal/permeability-increasing protein
13 CLAIMS
We claim:
1. A method of inhibiting mannuronic acid polymer-mediated stimulation of host inflammatory cells in the
presence of a cell-stimulating amount of a mannuronic acid polymer, said method comprising administering to
the host bactericidal/permeability-increasing protein (BPI) in an amount effective to inhibit inflammatory cell
stimulation.
2. The method of claim 1 wherein the mannuronic acid polymer comprises a gel having encapsulated therein
living implant cells, and an effective amount of BPI to inhibit stimulation of said inflammatory cell by said gel,
said effective amount being from about 1% to 100% by weight of the mannuronic acid polymer.
3. The method of claim 2 wherein the gel encapsulated cells are hormone-producing cells.
4. The method of claim 3 wherein the hormone-producing cells and the BPI are administered together in a
single composition or separate compositions.
5. The method of claim 3 wherein the hormone-producing cells are pancreatic islet cells.
6. A method of inhibiting mannuronic acid polymer-mediated tumor necrosis factor (TNF), IL-1 or IL-6
production by human host mononuclear cells in the presence of a cell-stimulating amount of a mannuronic acid
polymer, which comprises administering to a host bactericidal/permeability-increasing protein in an amount
effective to inhibit TNF, IL-1 or IL-6 production.
7. The method of claim 6 wherein the mannuronic acid polymer comprises a gel having encapsulated therein
living cells and an effective amount of a BPI to inhibit stimulation of said cells by said gel, said effective amount
of BPI being from about 1% to 100% by weight of the mannuronic acid polymer.
8. A composition comprising a mannuronic acid polymer and an effective amount of a
bactericidal/permeability-increasing protein (BPI) to inhibit inflammatory cell stimulation by said mannuronic
acid polymer, and optionally a physiologically or pharmaceutically acceptable carrier.
9. The composition of claim 8 wherein said mannuronic acid polymer is a gel having encapsulated therein
living cells.
10. The composition of claim 8, wherein said effective amount is from about 1% to 100% by weight of the
mannuronic acid polymer.
11. A method for preparing an encapsulated living cell composition substantially-free of inflammatory cell
stimulation activity, which comprises
(a) encapsulating living cells in a mannuronic acid polymer gel and
(b) admixing said gel with a bactericidal/permeability-increasing protein (BPI) optionally with a
physiologically or pharmaceutically acceptable carrier.
12. A kit for administration of a mannuronic acid polymer substantially free of inflammatory cell stimulation
activity comprising
(a) a bactericidal/permeability-increasing protein (BPI) and
(b) a mannuronic acid polymer,
wherein said (a) and (b) can be administered together or separately.
13. The kit of claim 12 wherein said mannuronic acid polymer has encapsulated therein living cells. |
